Inventor
STUART MILSTEIN
Inventor
US
Overview
Patents· 34 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C12NMicroorganisms or enzymes31%
A61KPreparations for medical, dental or toiletry purposes30%
C12YEnzymes5%
C07HSugars2%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
12,565,653ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof202612,467,051Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202512,460,206PCSK9 iRNA compositions and methods of use thereof202512,397,013Extrahepatic delivery202512,385,044Modified double-stranded RNA agents202512,385,043Modified double-stranded RNA agents202512,378,553Modified double-stranded RNA agents202512,359,20117ss-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof202512,227,744Compositions and methods for inhibiting expression of transthyretin202512,173,289Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof202412,168,767Modified double-stranded RNA agents202412,091,661Organic compositions to treat HSF1-related diseases202412,005,074Extrahepatic delivery202411,866,709Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202411,840,692Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202311,834,662Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202311,725,207Serpina1 iRNA compositions and methods of use thereof202311,725,209TMPRSS6 iRNA compositions and methods of use thereof202311,649,459Superoxide dismutase 1 (SOD1) iRNA compositions and methods of use thereof for treating or preventing superoxide dismutase 1-(SOD1-) associated neurodegenerative diseases202311,549,109Modified double-stranded RNA agents202311,525,138Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202211,504,391Modified RNA agents with reduced off-target effect202211,492,623Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof202211,427,822Modified double-stranded RNA agents202211,419,942Angiotensinogen (AGT) iRNA compositions and methods of use thereof202211,408,001Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof202211,401,517Modified double-stranded RNA agents202211,332,743Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202211,306,315Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202211,306,314Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202211,306,316Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof202211,261,444Organic compositions to treat EPAS1-related diseases202211,180,75717b-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof202111,142,766Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to ALNYLAM PHARMACEUTICALS INC (30)· patent assignee history
2021–2025Patents assigned to REGENERON PHARMA (2)· patent assignee history
2021–2026Based in US· patent location history
2022–2024Patents assigned to ARROWHEAD PHARMACEUTICALS INC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 30 | 2021–2026 |
| ARROWHEAD PHARMACEUTICALS INC | 2 | 2022–2024 |
| REGENERON PHARMA | 2 | 2021–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 34 | 2021–2026 |